文献速递慢性肾脏病肾血管病与高血压

盐与阿米洛利对ADPKD血管僵硬度影响的随机对照试验

Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD.
PubMed 文献 · Kidney Int Rep · 2026-09-23

在常染色体显性多囊肾病(ADPKD)成人中开展的雙盲随机安慰剂对照试验显示,口服氯化钠胶囊(6 g/d)2周可显著升高脉搏波传导速度(PWV)和24小时收缩压;阿米洛利(20 mg/d)未降低PWV,仅在低盐组降低收缩压。

要点

  • 补盐2周使ADPKD患者PWV和24小时收缩压显著升高。
  • 阿米洛利未降低PWV,仅在低盐条件下降低收缩压。
  • 支持早期ADPKD限盐以保护血压和血管。

核心结论

  • 在早期ADPKD中,膳食钠显著增加血管僵硬度
  • 阿米洛利仅在低盐条件下显著降低血压
  • 限盐是早期ADPKD血压和血管保护的实际策略

研究设计与样本

  • eGFR≥60 ml/min per 1.73 m2,先经2周低盐导入
  • 随机1:1接受口服氯化钠胶囊6 g/d或安慰剂2周
  • 随后两组均开放标签加用阿米洛利20 mg/d 2周

主要发现

  • 补盐组PWV从6.5±0.9 m/s升至6.8±1.1 m/s(P=0.02)
  • 补盐组24小时收缩压从133±13 mmHg升至138±15 mmHg(P=0.02)
  • 阿米洛利未降低PWV
  • 低盐组阿米洛利使收缩压从135±11降至130±13 mmHg(P=0.03)
  • 两组血钾轻度升高,无高钾血症

关键数值与推荐

  • 低盐导入期钠摄入≤3.5 g/d
  • 补盐剂量为口服氯化钠6 g/d
  • 阿米洛利剂量为20 mg/d

临床怎么用

  • 对早期ADPKD患者应强调膳食限盐以控制血压和血管僵硬度
  • 阿米洛利在低盐条件下可能有助于降压,但需监测血钾

局限性

  • 干预时间短(各2周)
  • 开放标签阿米洛利阶段

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with autosomal dominant polycystic kidney disease (ADPKD) often develop early vascular stiffening and hypertension. Dietary sodium may worsen vascular stiffness via epithelial sodium channel (ENaC) activation, and ENaC inhibition might mitigate this, but this remains untested in ADPKD. We hypothesized that dietary sodium loading increases vascular stiffness in ADPKD and that the ENaC inhibitor amiloride attenuates this effect. METHODS: In this double-blind, randomized, placebo-controlled trial, adults with ADPKD and estimated glomerular filtration rate (eGFR) ≥60 ml/min per 1.73 m2 completed a 2-week low-salt run-in (≤ 3.5 g/d), then were randomized 1:1 to oral sodium chloride capsules (6 g/d) or placebo for 2 weeks, followed by a 2-week open-label amiloride (20 mg/d) add-on phase in both arms. The primary outcome was pulse wave velocity (PWV). Secondary outcomes included 24-hour blood pressure (BP) and biochemical parameters. RESULTS: Thirty-seven participants (mean age 39 ± 11 years, eGFR 89 ± 19 ml/min per 1.73 m2) were randomized to salt (n = 19) or placebo (n = 18). Salt supplementation increased PWV (6.5 ± 0.9 m/s to 6.8 ± 1.1 m/s, P = 0.02) and 24-hour systolic BP (133 ± 13 mm Hg to 138 ± 15 mm Hg, P = 0.02). Amiloride did not reduce PWV in either group, but decreased systolic BP only in the low-salt group (135 ± 11 to 130 ± 13 mm Hg, P = 0.03). Plasma potassium increased modestly in both groups following amiloride, without hyperkalemia. CONCLUSION: In this small, short-term trial, dietary sodium significantly increased vascular stiffness and BP in early ADPKD, and amiloride significantly lowered BP only under low-salt conditions. These findings support dietary sodium restriction as a practical strategy for BP and vascular protection in early ADPKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Noruzi, Xue, Visser, et al. Randomized Controlled Trial of Salt and Amiloride on Vascular Stiffness in ADPKD. Kidney Int Rep. 2026. PMID: 42936279. doi:10.1016/j.ekir.2026.107110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。